Loading organizations...
§ Private Profile · Utrecht, Netherlands
Cell therapy company developing cancer immunotherapies using proprietary gamma/delta T cell receptors for oncology patients.
Gadeta has raised $7.8M across 1 funding round.
Key people at Gadeta.
Gadeta has raised $7.8M in total across 1 funding round.
Gadeta is a cell therapy company based in Utrecht, Netherlands, that develops cancer immunotherapies utilizing engineered gamma/delta T cell receptors to target both solid tumors and hematological cancers. The biotechnology firm has filed 11 patents for its proprietary platform, which is specifically designed to recognize unique patterns on cancer cell surfaces while sparing surrounding healthy tissue. Prior to its recent acquisition, the enterprise raised $7.8 million in total funding from a syndicate of venture capital and corporate investors, including Medicxi Ventures and Gilead Sciences. The organization also established strategic research collaborations with prominent industry partners such as Kite Pharma and Immunocore before being acquired by Clade Therapeutics in October 2023. Operating today as a wholly owned subsidiary of Clade Therapeutics with its shareholders receiving downstream economic payments, Gadeta was founded in 2015 by Mark de Boer.
Key people at Gadeta.
Gadeta has raised $7.8M across 1 funding round. Most recently, it raised $7.8M Series A in March 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 29, 2016 | $7.8M Series A | Geeta Vemuri, Giovanni Mariggi | Utrecht Holdings | Announced |
Gadeta has raised $7.8M in total across 1 funding round.
Gadeta's investors include Geeta Vemuri, Giovanni Mariggi, Utrecht Holdings.
Gadeta is a biotechnology company specializing in the development of innovative immunotherapies for cancer, particularly focusing on solid tumors and hematological malignancies. Its core product platform engineers gamma/delta (γ/δ) T cell receptors (TCRs) that uniquely recognize cancer-specific surface targets, enabling precise targeting and elimination of tumor cells while sparing healthy tissue. Gadeta primarily serves the oncology healthcare sector, aiming to address the unmet need for effective cell therapies against solid tumors where existing treatments have limited success. The company has demonstrated growth momentum through its proprietary platform and pipeline advancement, culminating in its acquisition by Clade Therapeutics in October 2023, which aims to accelerate clinical development and commercialization of its off-the-shelf cell therapy products[1][2][4].
Founded in 2015 and headquartered in Utrecht, Netherlands, Gadeta was established to pioneer novel cell therapies based on γ/δ TCR technology. The founding team leveraged deep expertise in immunology and cell therapy to develop a platform that exploits the natural tumor surveillance capabilities of γ/δ T cells. Early traction came from advancing a pipeline of novel TCRs capable of targeting a broad range of solid tumors and hematological cancers, a significant step given the challenges in treating solid tumors with cell therapies. The company’s evolution culminated in its strategic acquisition by Clade Therapeutics, reflecting its maturation from a research-driven startup to a key player in engineered cell therapies[1][2].
Gadeta is riding the wave of next-generation cell therapies that aim to overcome limitations of current CAR-T and TCR-T treatments, especially in solid tumors. The timing is critical as advances in immuno-oncology, gene editing, and cell engineering converge to enable more effective, scalable, and safer therapies. Market forces such as increasing cancer incidence, demand for personalized medicine, and regulatory support for innovative biologics favor Gadeta’s approach. By developing universal γ/δ TCR-based therapies, Gadeta contributes to expanding the applicability of cell therapies beyond hematological malignancies, influencing the broader ecosystem toward more versatile and off-the-shelf immunotherapies[2][4].
Post-acquisition by Clade Therapeutics, Gadeta is positioned to accelerate clinical translation of its γ/δ TCR platform, potentially bringing first-in-class off-the-shelf cell therapies for solid tumors to market. Future trends shaping its journey include advances in stem cell engineering, improved manufacturing scalability, and deeper understanding of tumor immunology. Gadeta’s influence may grow as it helps validate γ/δ TCRs as a new modality in cancer immunotherapy, potentially reshaping treatment paradigms for solid tumors. Continued innovation and clinical success could establish Gadeta as a leader in universal cell therapies, fulfilling its mission to improve outcomes for cancer patients worldwide[2].
